Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02196038
Other study ID # IRB00028221
Secondary ID R01AG045551
Status Completed
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date July 27, 2020

Study information

Verified date September 2020
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients, is a multicenter, randomized, attention-controlled, single-blind trial designed to examine the hypothesis that, in addition to standard care, a novel, tailored, progressive, multi-domain rehabilitation intervention administered to older patients with acute decompensated heart failure (ADHF) beginning early during hospitalization and continuing for 12 weeks will improve physical function and key clinical outcomes, including the rate of rehospitalization.


Description:

There will be three lead centers, Wake Forest Baptist Health along with Thomas Jefferson University and Hospital-Co-Investigator Dr. David Whellan, and Duke University Medical Center-Co-Investigator Dr. Christopher O'Connor. Each center may recruit up to 3 geographically close, tightly affiliated 'satellite' sites under their management and budgetary control. Together, these sites will recruit a total of 352 consenting patients ≥ 60 years old hospitalized with ADHF. Following informed consent and baseline testing, the participants will be randomized in a 1:1 fashion to receive a 12-week novel, progressive, multi-domain rehabilitation and exercise training intervention or attention control. The multi-domain rehabilitation intervention will include endurance, mobility, strength, and balance training and will be tailored based on participant performance in each of these domains. It will begin upon randomization during the hospitalization and will continue 3 times per week in an outpatient setting. Participants randomized to the attention control arm will receive all services ordered by their primary physician and will be contacted bi-weekly by study staff. All participants will undergo measures of physical function and quality of life at baseline, 1 month, and 3 months. Clinical events will be monitored for 6 months following the index hospitalization.


Recruitment information / eligibility

Status Completed
Enrollment 349
Est. completion date July 27, 2020
Est. primary completion date June 15, 2020
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Age = 60 years old - In the hospital setting >24 hours for the management of ADHF, or diagnosed with ADHF after being hospitalized for another reason. ADHF will be confirmed by the study physician, and will be defined according to the Food and Drug Administration definition of hospitalized heart failure as a combination of symptoms, signs, and HF-specific medical treatments. Exclusion Criteria: - Acute myocardial infarction - Planned discharge other than to home or a facility where the participant will live independently - Already actively participating in formal, facility-based cardiac rehabilitation

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
multi-domain rehabilitation intervention
Individual, tailored, progressive physical function rehabilitation intervention
Attention Control
Usual care with bi-weekly contact from study staff

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina
United States Thomas Jefferson University and Hospital Philadelphia Pennsylvania
United States Wake Forest Baptist Health Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Health Sciences National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other 6-minute Walk Distance Exploratory outcome. Distance walked in 6 minutes. Month 3
Other Handgrip Strength Exploratory outcome. Handgrip strength is measured in kilograms by a handgrip dynamometer. Month 3
Other Frailty Status (Fried Frailty Criteria) at Month 3 Exploratory outcome. Frailty is assessed by the Fried criteria consisting of 5 components: low physical activity, exhaustion, weakness, slowness, and unintentional weight loss. Presence of 3 or more Fried criteria indicates frailty, 1-2 criteria indicates pre-frailty, and 0 criteria indicates no frailty. Month 3
Other Quality of Life Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score Exploratory outcome. The KCCQ Overall Summary Summary Score is a heart failure disease-specific quality of life measure encompassing domains of physical limitation, HF symptoms, quality of life, and social limitation scored on a scale of 0-100 with higher scores indicating better health status. Month 3
Other Physical Limitation as Assessed by the KCCQ Physical Limitation Score Exploratory outcome. The Physical Limitation Score of the KCCQ questionnaire is a subscore evaluating disease-specific physical limitation. Scores range 0-100 with a higher score indicating less physical limitation. Month 3
Other Quality of Life Measured by Short Form 12 Item Questionnaire (SF-12) Exploratory outcome. The SF-12 is a quality of life assessment with 2 component scores (Physical Composite Score and Mental Composite Score) ranging 0-100 with higher scores indicating better health status. Month 3
Other Quality of Life Assessed by the EuroQol 5-dimension 5-level (EQ-5D-5L) Exploratory outcome. The EQ-5D-5L is a quality of life tool with 5 components designed to detect health utilities: mobility, usual activities, self-care, pain/discomfort, and anxiety/depression. All components are rated on a scale of 1-5 with higher scores indicating worse health status. Month 6
Other Depression Measured by the Geriatric Depression Scale Exploratory outcome. The Geriatric Depression Scale is a 15-item questionnaire evaluating depressive symptoms. Scores range from 0-15 with a higher score indicating more severe depressive symptoms. Month 3
Other Cognitive Function Measured by the Montreal Cognitive Assessment (MoCA) Exploratory outcome. The Montreal Cognitive Assessment is a tool for assessing multiple domains of cognitive function. Scores range 0-30 with higher scores indicating better cognitive function. A score greater than or equal to 26 is considered normal cognitive function. Month 3
Other All-cause Rehospitalizations at Month 1 Exploratory outcome. Number of all-cause rehospitalizations 1 month post index hospitalization discharge. Month 1
Other All-cause Rehospitalizations at Month 3 Exploratory outcome. Number of all-cause rehospitalizations 3 months after discharged from index hospitalization Month 3
Other All-cause Combined Rehospitalization and Death at Month 6 Exploratory outcome. Combined number of all-cause rehospitalizations and death 6 months after discharge from index hospitalization Month 6
Other Heart Failure Rehospitalizations at Month 6 Exploratory outcome. Number of heart failure rehospitalizations 6 months after discharge from index hospitalization Month 6
Other Hospitalization Days Post-randomization Exploratory outcome. Total days spent hospitalized after date of randomization. Month 6
Other Facility-free Days Alive Exploratory outcomes. Total days alive spent outside of hospital, observation unit, acute rehab setting, and skilled nursing facility 6 months after discharge from index hospitalization. Month 6
Other Emergency Department Visits Exploratory outcomes. Number of emergency department visits after 6 months from hospital discharge Month 6
Other Observation Unit Stays <24 Hours Exploratory outcome. Number of observation unit stays <24 hours 6 months after discharge from index hospitalization Month 6
Other Unscheduled Urgent Medical Visits Exploratory outcome. Number of unscheduled urgent medical visits after discharge from index hospitalization Month 6
Other Global Rank Score of Short Physical Performance Battery Score + All-cause Rehospitalization + Death Exploratory outcome. The global rank composite outcome combines non-commensurate endpoints including death, number of all-cause rehospitalizations, and month 3 SPPB into a single non-parametric outcome in a hierarchical manner with death being ranked first and SPPB being ranked last. Participants are ranked from the most adverse response (lowest rank) to the most favorable response (highest rank). Month 6
Other Placement at Skilled Nursing Facility Exploratory outcome. Number of placements at skilled nursing facilities after discharge from index hospitalization. Month 6
Other Physical Activity Assessed by Accelerometry Exploratory outcome. Physical activity assessed by accelerometry quantified in moderate-vigorous physical activity minutes per day. Month 6
Other Generalized Optimism Assessed by the Life Orientation Test-Revised Exploratory outcome. The Life Orientation Test-Revised is a assessment of generalized optimism scored on a scale of 0-24 with higher scores indicating higher optimism. Month 3
Other Economic Analysis Assess direct medical costs, direct non-medical costs, indirect patient time costs, short-term cost-analysis, long-term cost analysis, and sustainability of the intervention. Month 6
Other Biomarkers Two well-accepted biomarkers of HF disease severity and prognosis, NT-proBNP and galectin-3, and increased biomarkers in older HF patients Tumor necrosis factor alpha, C-reactive protein, and interleukin-6. Month 3
Primary Short Physical Performance Battery (SPPB) at Month 3 The Short Physical Performance Battery is scored on a scale of 0-12, with a higher score indicating better physical function. Month 3
Secondary All-Cause Rehospitalization Number of all-cause rehospitalizations 6 months from index hospital discharge. Month 6
See also
  Status Clinical Trial Phase
Completed NCT04049045 - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Recruiting NCT02898181 - Low Level Tragus Stimulation in Acute Decompensated Heart Failure N/A
Completed NCT02823626 - High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Completed NCT00693745 - Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF N/A
Not yet recruiting NCT04391231 - HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial Phase 4
Recruiting NCT05206422 - DORAYA-HF Early Feasibility Study N/A
Recruiting NCT01960218 - Gas Exchange for Predicting Hospital Heart Failure Readmissions N/A
Terminated NCT00904488 - Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Phase 4
Terminated NCT02620384 - Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. Phase 3
Completed NCT04318093 - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Phase 2
Recruiting NCT06161649 - Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure N/A
Completed NCT02289508 - Role of USCOM in Adult Patients With Heart Failure N/A
Terminated NCT01457053 - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics N/A
Completed NCT04877652 - DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
Completed NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Completed NCT03146754 - A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE) N/A
Terminated NCT05346653 - The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure Phase 4
Withdrawn NCT02721511 - A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen Phase 1/Phase 2